MAPT and Alzheimer disease: Tarawneh et al. (71) have reported that CSF VILIP-1 levels differ between AD and normal cognitive subjects (520 versus 396 pg/ml, respectively) and correlate with CSF t-tau, p-tau-181, and brain volumes in AD.